The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 25, 2017
Filed:
May. 12, 2011
Jean-damien Charrier, Wantage, GB;
Hayley Marie Binch, Encinitas, CA (US);
Dennis James Hurley, San Marcos, CA (US);
Thomas Cleveland, San Diego, CA (US);
Pramod Joshi, San Diego, CA (US);
Lev Tyler Dewey Fanning, San Marcos, CA (US);
Joanne Pinder, Didcot, GB;
Michael O'donnell, Abingdon, GB;
Anisa Nizarali Virani, Thatcham, GB;
Ronald Marcellus Alphonsus Knegtel, Abingdon, GB;
Steven John Durrant, Abingdon, GB;
Stephen Clinton Young, Oxford, GB;
Pierre-henri Storck, Abingdon, GB;
David Kay, Wiltshire, GB;
Philip Michael Reaper, Shillingford, GB;
Matthew Paul Grote, New York, NY (US);
Jean-Damien Charrier, Wantage, GB;
Hayley Marie Binch, Encinitas, CA (US);
Dennis James Hurley, San Marcos, CA (US);
Thomas Cleveland, San Diego, CA (US);
Pramod Joshi, San Diego, CA (US);
Lev Tyler Dewey Fanning, San Marcos, CA (US);
Joanne Pinder, Didcot, GB;
Michael O'Donnell, Abingdon, GB;
Anisa Nizarali Virani, Thatcham, GB;
Ronald Marcellus Alphonsus Knegtel, Abingdon, GB;
Steven John Durrant, Abingdon, GB;
Stephen Clinton Young, Oxford, GB;
Pierre-Henri Storck, Abingdon, GB;
David Kay, Wiltshire, GB;
Philip Michael Reaper, Shillingford, GB;
Matthew Paul Grote, New York, NY (US);
Vertex Pharmaceuticals Incorporated, Boston, MA (US);
Abstract
The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.